Matthew Meyer will lead the session: "Successfully Expanding into the U.S. Life Science Market."

For many high-growth European-based technology and life science enterprises, the United States is the most attractive country for expansion and/or fundraising. The U.S. offers the promise of massive commercial opportunities, strategic partnerships and plentiful venture and growth capital. However, doing business and raising money in an unfamiliar, highly-competitive environment requires thoughtful advance planning and clinical execution. In this facilitated presentation and Q&A to follow, we will discuss best practices for navigating the logistical aspects of launching and operating a business in America and setting and meeting expectations for U.S. later-stage funding. We will cover a number of frequently asked questions, such as: When should I consider establishing U.S. operations? When should I look to raise money from U.S. VCs? Do I need a U.S. company to raise money from U.S. VCs? When do I need to create a U.S. company? How long does U.S. set up take and how much does it cost? How do I sell/pitch in the U.S. as a non-U.S. founder? Does everyone really sue each other all the time in the U.S.? Is there any method to limit our liability?